Abstracts tagged "Anakinra"

Abstract Number: 2090 • 2017 ACR/ARHP Annual Meeting
Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with Veterans Affairs Medical Center
Julianna Desmarais¹ and Cong-Qiu Chu², ¹Department of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Rheumatology, Oregon Health & Science University, Portland, OR
Background/Purpose: Anakinra is an IL-1 blocking medication used off label to relieve acute inflammation from gout and pseudogout. The efficacy and safety of this treatment…
Abstract Number: 169 • 2017 ACR/ARHP Annual Meeting
New Autoinflammatory Phenotype Associated with Homozygous AGBL3 Variant
Ahmet Gül¹, Neslihan Abaci² and Sema Sirma Ekmekci², ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Genetics, Istanbul University Institute for Experimental Medical Research, Istanbul, Turkey
Background/Purpose: To identify new genes/pathways associated with autoinflammatory phenotype. Methods: We screened genomic variations by whole exome sequencing in 3 families presented with autoinflammatory findings…
Abstract Number: 368 • 2017 ACR/ARHP Annual Meeting
Evaluation of Efficacy and Safety of Opocalcium Colchicine, and Anti-IL1 Treatment in Childhood Colchicine-Resistant Familial Mediterranean Fever
Kenan Barut, Amra Adrovic, Sezgin Sahin, Asli Kaplan and Ozgur Kasapcopur, Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: The colchicine-resistant FMF (crFMF) is defined as 6 or more polyserositis attacks in the last year despite the regular usage of colchicine in the…
Abstract Number: 940 • 2017 ACR/ARHP Annual Meeting
IL1RN Variation Is Associated with Systemic Juvenile Idiopathic Arthritis and Predicts Non-Response to Anakinra Treatment
Emily Shuldiner¹, Victoria Arthur¹, Anne Hinks², Patricia Woo³, Wendy Thomson², Elaine F. Remmers⁴ and Michael J. Ombrello¹, ¹Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, ²Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ³University College London, London, United Kingdom, ⁴Genetics and Genomics Branch, NIH, NIAMS, Bethesda, MD
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a childhood inflammatory disease whose pathophysiology is poorly understood. sJIA is phenotypically heterogeneous with variable manifestations and responses…
Abstract Number: 74 • 2017 Pediatric Rheumatology Symposium
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
Esraa M. A. Eloseily^1,2, Peter Weiser¹, Hilary Haines³, Melissa Mannion⁴, Matthew L. Stoll¹, Timothy Beukelman¹, Prescott Atkinson⁵ and Randy Q. Cron¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Pediatrics, Assiut University, Assiut, Egypt, ³Pediatric Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, ⁴Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatric Allergy and Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Familial, or primary, hemophagocytic lymphohistiocytosis (pHLH), is a rare but highly fatal condition due to mutations in lymphocyte cytolytic pathway genes. Secondary HLH (sHLH),…
Abstract Number: 214 • 2016 ACR/ARHP Annual Meeting
Anakinra Compared to Prednisone on the Treatment of Acute CPPD Crystal Arthritis, a Randomized, Controlled, Double-Blind Study
Alexandre Dumusc¹, Borbala Pazar Maldonado¹, Charles Benaim², Isabelle Fabreguet¹, Pascal Zufferey¹, Bérengère Aubry-Rozier¹ and Alexander So¹, ¹Rheumatology Department, Lausanne University Hospital, Switzerland, Lausanne, Switzerland, ²Physical Medicine and Rehabilitation Department, Lausanne University Hospital, Switzerland, Lausanne, Switzerland
Background/Purpose: Calcium pyrophosphate crystal-induced arthritis (CPPD) is an acute crystal arthritis, frequently involving the wrist or the knee. Monosodium urate in gout or CPPD…
Abstract Number: 215 • 2016 ACR/ARHP Annual Meeting
Anakinra Is Effective and Well Tolerated in Medically Complex Patients Including Transplant Recipients with Gout
Christopher Palma¹, Taylor Topping² and Darren Tabechian¹, ¹Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Pharmacy, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Anakinra is a biologic response modifier that competitively antagonizes the biologic effects of interleukin-1β. Conventional treatments for the inflammatory response to acute gout are…
Abstract Number: 247 • 2016 ACR/ARHP Annual Meeting
ANTI-Interleukin 1 Therapy in FMF Amyloidosis: A Single Center Experience
Serdal Ugurlu, Bilgesu Ergezen and Huri Ozdogan, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: Recently there is increasing number of reports pointing out the efficacy of anti-interleukin 1(anti-IL1)therapy to control AA amyloidosis secondary to autoinflammatory diseases. Here we…
Abstract Number: 942 • 2016 ACR/ARHP Annual Meeting
A Nationwide Experience with the Off Label Use of Interleukin 1 Targeting Treatment in Familial Mediterranean Fever Patients
Servet Akar¹, Pınar Cetin², Umut Kalyoncu³, Omer Karadag⁴, Ismail Sari⁵, Muhammed Cinar⁶, Sedat Yılmaz⁷, Ahmet Mesut Onat⁸, Bunyamin Kisacik⁹, Abdulsamet Erden³, Ayşe Balkarli¹⁰, Orhan Kucuksahin¹¹, Sibel Yilmaz Oner¹², Soner Senel¹³, Abdurrahman Tufan¹³, Haner Direskeneli¹², Mustafa Ferhat Oksuz¹⁴, Yavuz Pehlivan¹⁴, Ozun Bayndır¹⁵, Gokhan Keser¹⁶, Kenan Aksu¹⁷, Ahmet Omma¹⁸, Timucin Kasifoglu¹⁹, Ali Ugur Unal²⁰, Fatih Yildiz²¹, Mehmet Ali Balci²², Sule Yavuz¹³, Sukran Erten²³, Metin Ozgen²⁴, Mehmet Sayarlioglu²⁵, Atalay Dogru²⁶, Gozde Yildirim Cetin²⁷, Fatma Alibaz-Oner²⁰, Mehmet Engin Tezcan²⁸, Omer Nuri Pamuk²⁹ and Fatos Onen³⁰, ¹Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ²Dokuz Eylul University, izmir, Turkey, ³Hacettepe University, Ankara, Turkey, ⁴Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁵Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ⁶GATA, Ankara, Turkey, ⁷Division of Rheumatology, Gülhane Military Medical Academy, School of Medicine, Ankara, Turkey, ⁸Gaziantep University School of Medicine, Ankara, Turkey, ⁹Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ¹⁰Antalya EAH, Antalya, Turkey, ¹¹Internal Medicine-Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, ¹²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ¹³PsART study group, Ankara, Turkey, ¹⁴Rheumatology, Uludag University Medcal Faculty, Bursa, Turkey, ¹⁵İnternal Medicine Division of Rheumatology, Ege University Medical Faculty, Izmir, Turkey, ¹⁶Rheumatology, Ege University Medical Faculty, Izmir, Turkey, ¹⁷Ege University, İzmir, Turkey, ¹⁸Department of Internal Medicine, Rheumatology Division, Ankara Numune Hospital, Ankara, Turkey, ¹⁹İnternal Medicine Division of Rheumatology, Osmangazi University, Faculty of Medicine, Eskisehir, Turkey, ²⁰Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ²¹Rheumatology, Van EAH, Adana, Turkey, ²²Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²³Rheumatology, Yildirim Beyazit University Faculty Of Medicine, Ankara, Turkey, ²⁴Department of Internal Medicine Division of Rheumatology, Ondokuz Mayıs University, Faculty of Medicine, Samsun, Turkey, ²⁵Rheumatology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey, ²⁶Suleyman Demirel University, Isparta, Turkey, ²⁷Deparment of Rheumatology, Sutcu Imam University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, Turkey, ²⁸Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ²⁹Rheumatology, Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, Edirne, Turkey, ³⁰Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey
Background/Purpose: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease and colchicine is the mainstay of treatment. Around 30-45% of FMF patients were reported…
Abstract Number: 259 • 2015 ACR/ARHP Annual Meeting
How Safe IT Is to TREAT Pregnant FMF Patients with Anakinra ?
Huri Ozdogan¹, Serdal Ugurlu² and Bilgesu Ergezen¹, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: To assess the safety and efficacy of anakinra in pregnant FMF patients. Methods: Six FMF patients, treated with anakinra during pregnancy were monitored for…
Abstract Number: 261 • 2015 ACR/ARHP Annual Meeting
Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-Center Experience
Serdal Ugurlu¹, Bilgesu Ergezen² and Huri Ozdogan², ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Turkey, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: To review the patients followed in our center with FMF who received anakinra, an anti IL-1 receptor antagonist, because of insufficient colchicine response. Methods: FMF…
Abstract Number: 265 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Compared with Anakinra in Refractory Adult-Onset Still’s Disease. Multicenter Study of 75 Patients
Leyre Riancho-Zarrabeitia¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Jose L. Hernández², Francisco Ortiz-Sanjuán¹, Alejandro Olivé³, Anne Riveros Frutos⁴, Santos Castañeda⁵, Javier Narváez⁶, Maria Luisa Velloso Feijoo⁷, M. Victoria Hernández⁸, Alberto Sifuentes Giraldo⁹, Olga Maiz-Alonso¹⁰, Esteban Rubio Romero¹¹, Cristina Mata-Arnaiz¹², Adela Gallego Flores¹³, Jordi del Blanco¹⁴, Catalina Gómez-Arango¹⁵, Sara Manrique-Arija¹⁶, Maria Carmen Ordoñez¹⁷, Inmaculada Ros Vilamajo¹⁸, Miguel Angel Caracuel-Ruiz¹⁹, Mercedes Freire²⁰, Jose Llobet²¹, Carlos Marras²², Concepción Moll Tuduri²³, Chamaida Plasencia²⁴, Rosa Roselló²⁵, Ana Urruticoechea²⁶, Inmaculada Jiménez-Moleón²⁷, José Antonio Bernal²⁸, Vera Ortiz-Santamaría²⁹, Juan Ramón De Dios³⁰, Mireia Moreno³¹, Jordi Fiter³², Marina de los Riscos³³, Patricia E. Carreira³³, María José Rodríguez Valls Sr.³⁴, Carmen Gonzalez-Vela³⁵, Javier Loricera¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Rheumatology, Hospital U German Trias i Pujol, Badalona, Spain, ⁴Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁵Rheumatology, H.U. La Princesa, Madrid, Spain, ⁶Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷H Valme, Sevilla, Spain, ⁸Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, ⁹Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹⁰Rheumatology, HU Donostia, San Sebastián, Spain, ¹¹Rheumatology Department,, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹²Rheumatology, Hospital Laredo, Santander, Spain, ¹³Rheumatology, Hospital de Mérida, Mérida, Spain, ¹⁴Rheumatology, H Sant Jaume, Calella, Spain, ¹⁵Rheumatology, Hospital Basurto,, Santander, Spain, ¹⁶Rheumatology, Hospital Universitario Carlos Haya, Malaga, Spain, ¹⁷HRU Carlos Haya, Malaga, Spain, ¹⁸Hospital Son Llàtzer, Palma de Mallorca, Spain, ¹⁹Plaza Cruz Roja, 1, Hospital Reina Sofia, Córdoba, Spain, ²⁰Hospital Universitario Juan Canalejo, La Coruña, Spain, ²¹Hospital San Pau, Barcelona, Spain, ²²Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ²³H Mateu Orfila, Mahón, Spain, ²⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ²⁵H San Jorge, Huesca, Spain, ²⁶Hospital Can Misses, Ibiza, Spain, ²⁷Rheumatology, Hospital San Cecilio, Granada, Spain, ²⁸Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²⁹Rheumatology, Hospital General. Granollers., Granollers, Spain, ³⁰Rheumatology, HU Álava, Vitoria, Spain, ³¹Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain, ³²Rheumatology, HU Son Espases. Palma de Mallorca., Palma de Mallorca, Spain, ³³Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ³⁴Rheumatology, Rheumatolgy Unit. Hospital Jerez, Jerez, Spain, ³⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Interleukin (IL)-1 and IL-6 are pivotal cytokines in the pathogenesis of adult-onset Still’s disease (AOSD). Our aim was to compare the efficacy and safety of…
Abstract Number: 1449 • 2015 ACR/ARHP Annual Meeting
The Effect of IL-1 Receptor Antagonist Anakinra (Kineret®) on Measures of Central Nervous System Inflammation and Headaches in Pediatric Patients with Severe Cryopyrin-Associated Periodic Syndromes
Hans Olivecrona¹, Raphaela Goldbach-Mansky², Torbjörn Kullenberg¹ and Mika Leinonen³, ¹Swedish Orphan Biovitrum, Stockholm, Sweden, ²Translational Autoinflammatory Diseases Section, NIAMS, NIH, Bethesda, MD, ³4Pharma AB, Stockholm, Sweden
Background/Purpose: Cryopyrin-Associated Periodic Syndromes (CAPS) include a group of rare inherited autoinflammatory diseases consisting of Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome and the most…
Abstract Number: 3077 • 2015 ACR/ARHP Annual Meeting
Anakinra in Patients with Cortico-Dependent Idiopathic Recurrent Pericarditis: A Randomised Double-Blind Placebo-Controlled Withdrawal Trial
Antonio Brucato¹, Massimo Imazio², Silvia Maestroni¹, Davide Faustino Cumetti³, Anna Valenti¹, Renzo Marcolongo⁴, George Lazaros⁵, Mara Carraro², Fiorenzo Gaita², Gian Luca Erre⁶, Martina Finetti⁷, Marco Gattorno⁷ and Alberto Martini⁸, ¹Internal Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, ²Cardiology, Maria Vittoria Hospital, Torino, Italy, ³Internal Medicine, Internal Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, ⁴Clinical Immunology, Hospital of Padova, Padova, Italy, ⁵Department of Cardiology, Hippokration General Hospital, Athens, Greece, ⁶Rheumatology, Hospital of Sassari, Sassari, Italy, ⁷Pediatry, G. Gaslini Institute, Genova, Italy, ⁸Istituto G. Gaslini, Pediatria II, PRINTO, and University of Genoa, Genoa, Italy
Background/Purpose: Patients with recurrent pericarditis either do not respond or are intolerant to treatment with NSAIDs drugs, corticosteroids and colchicine. We aimed to assess the…
Abstract Number: 3094 • 2015 ACR/ARHP Annual Meeting
Dose Adjustment of Anakinra (Kineret®) Based on Clinical Response in Patients with Severe Cryopyrin-Associated Periodic Syndromes
Bengt Hallen¹, Torbjörn Kullenberg¹, Mika Leinonen², Margareta Wiken¹, Raphaela Goldbach-Mansky³ and Hans Olivecrona¹, ¹Swedish Orphan Biovitrum, Stockholm, Sweden, ²4Pharma AB, Stockholm, Sweden, ³Translational Autoinflammatory Diseases Section, NIAMS, NIH, Bethesda, MD
Background/Purpose: Cryopyrin-Associated Periodic Syndromes (CAPS) include a group of rare inherited autoinflammatory diseases consisting of Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome and the most…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].